menu

Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can cause recurrent and disabling bleeding, leading to severe arthropathy or life- threatening hemorrhage. Prophylaxis is well-documented for its effectiveness in preventing arthropathy and life-threatening bleeds, and improving total bleeding rates. However, limitations of modern factor replacement treatment result in suboptimal outcomes, poor adherence to prophylactic regimens, and reduced QoL. Novel and emerging prophylactic therapies can mitigate some of the hindrances of traditional replacement therapy and enhance the overall effect of treatment in hemophilia A.

    In this educational activity, expert faculty will review recent evidence from key clinical trials of prophylactic therapies that are expanding the armamentarium of therapeutic choices, including a novel high-sustained factor VIII replacement therapy, a bispecific antibody non-factor replacement therapy, and other emerging therapies. Evaluating patients’ goals and preferences will also be discussed, so clinicians can co-create treatment plans using a shared decision approach to improve adherence and reduce bleeding episodes in patients with hemophilia A.

  • Disclosure of Relevant Financial Relationships

    Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Guy Young, MD reported the following relevant financial relationships or relationships he has with ineligible companies of any amount during the past 24 months: Consultant; Bayer HealthCare Pharmaceuticals, BioMarin, Centessa, CSL Behring, Genentech/Roche, Hema Biologics/LF, Novo Nordisk, Octapharma, Pfizer, Inc., Sanofi/Genzyme, Spark and Takeda Oncology. Speaker; CSL Behring, Hema Biologics, Sanofi. Received research grant from; Genentech, Inc., and Takeda Oncology. Contracted research; Genentech, Inc., and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.



  • Target Audience

    This activity is designed for hematologists, surgeons, pathologists/lab professionals, advanced practitioners (nurse practitioners, pharmacists, physician assistants, physical therapists), orthopedic specialists, primary care, pediatricians, emergency medicine, social workers, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with hemophilia A.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Apply up-to-date evidence to enable optimal timing for prophylactic treatment initiation in patients with hemophilia A to minimize long-term complications.
    2. Select appropriate prophylactic therapy for patients with hemophilia A based on clinical evidence, bleeding episode frequency, and patient preferences.
    3. Implement shared decision-making strategies when discussing appropriate prophylactic treatment that prevents undue bleeding episodes and increases adherence in patients with hemophilia A.
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
     This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

     Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until August 16, 2024 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists

     This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-23-028-H01-P.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     Laboratory Professionals

    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credits. ASCP CMLE credits are acceptable to meet the continuing education requirement for  the ASCP Board of Registry Certification Maintenance Program.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by

  • Commercial Support

    This educational activity is supported by an educational grant from Sanofi.

     

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can cause recurrent and disabling bleeding, leading to severe arthropathy or life- threatening hemorrhage. Prophylaxis is well-documented for its effectiveness in preventing arthropathy and life-threatening bleeds, and improving total bleeding rates. However, limitations of modern factor replacement treatment result in suboptimal outcomes, poor adherence to prophylactic regimens, and reduced QoL. Novel and emerging prophylactic therapies can mitigate some of the hindrances of traditional replacement therapy and enhance the overall effect of treatment in hemophilia A.

    In this educational activity, expert faculty will review recent evidence from key clinical trials of prophylactic therapies that are expanding the armamentarium of therapeutic choices, including a novel high-sustained factor VIII replacement therapy, a bispecific antibody non-factor replacement therapy, and other emerging therapies. Evaluating patients’ goals and preferences will also be discussed, so clinicians can co-create treatment plans using a shared decision approach to improve adherence and reduce bleeding episodes in patients with hemophilia A.

  • Disclosure of Relevant Financial Relationships

    Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Guy Young, MD reported the following relevant financial relationships or relationships he has with ineligible companies of any amount during the past 24 months: Consultant; Bayer HealthCare Pharmaceuticals, BioMarin, Centessa, CSL Behring, Genentech/Roche, Hema Biologics/LF, Novo Nordisk, Octapharma, Pfizer, Inc., Sanofi/Genzyme, Spark and Takeda Oncology. Speaker; CSL Behring, Hema Biologics, Sanofi. Received research grant from; Genentech, Inc., and Takeda Oncology. Contracted research; Genentech, Inc., and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.



  • Target Audience

    This activity is designed for hematologists, surgeons, pathologists/lab professionals, advanced practitioners (nurse practitioners, pharmacists, physician assistants, physical therapists), orthopedic specialists, primary care, pediatricians, emergency medicine, social workers, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with hemophilia A.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Apply up-to-date evidence to enable optimal timing for prophylactic treatment initiation in patients with hemophilia A to minimize long-term complications.
    2. Select appropriate prophylactic therapy for patients with hemophilia A based on clinical evidence, bleeding episode frequency, and patient preferences.
    3. Implement shared decision-making strategies when discussing appropriate prophylactic treatment that prevents undue bleeding episodes and increases adherence in patients with hemophilia A.
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
     This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

     Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until August 16, 2024 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists

     This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-23-028-H01-P.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     Laboratory Professionals

    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credits. ASCP CMLE credits are acceptable to meet the continuing education requirement for  the ASCP Board of Registry Certification Maintenance Program.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by

  • Commercial Support

    This educational activity is supported by an educational grant from Sanofi.

     

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Facebook Comments

Schedule20 Jun 2024